(AOF) – The biotech Hybrigenics announces that it “records a record year in terms of investment” while its subsidiaries have been granted 4 million euros to finalize their respective structuring phases. Each “now has an operational platform capable of addressing its markets with a high added value offer” and Hybrigenics “is on the way to achieving its ambition of becoming a group bringing together research, production and distribution on a common technological platform. “.
These investments were made possible thanks to the financing contract with Iris set up in March 2021: this contract for the issue and subscription of bond issue warrants redeemable in new shares (Beora) was the subject of an amendment dated March 13, 2023 to extend his commitment period: increased to 48 months. this period will end on March 19, 2025 instead of March 19, 2023.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.